Preparation method of 2-[(3-oxo-2-azaspiro [4, 5] decane-2-yl) methyl]-2-azaspiro [4, 5] decane-3-ketone
By reacting 2-azaspiro[4,5]decane-3-one with formaldehyde or paraformaldehyde under an acidic catalyst and purifying it, the problem of large-scale production of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one was solved, and the preparation of the target impurity with high purity and low cost was achieved, meeting the needs of drug research.
Patent Information
- Application Number
- CN202411080758.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-29
AI Technical Summary
Existing technologies cannot mass-produce 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one, making it expensive and difficult to obtain, which affects the quality control of gabapentin products.
High-purity 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one was obtained by reacting 2-azaspiro[4,5]decane-3-one, formaldehyde or paraformaldehyde with an acidic catalyst in a solvent and then purifying it.
It has achieved the targeted synthesis of high-purity (>97%) target impurities at a cost significantly lower than commercially available prices, meeting the requirements for drug research and quality control.
Smart Images

Figure CN119039206A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of gabapentin impurity preparation, and in particular to a method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one. Background Art
[0002] Gabapentin is a well-tolerated anticonvulsant that is not metabolized in the body, does not bind to proteins, does not induce liver enzymes, and does not interact with other drugs. It is an ideal anti-epileptic drug, and oral administration is not affected by food, and does not require blood drug concentration monitoring. It is suitable for epilepsy patients who are ineffective or cannot be satisfactorily controlled by conventional anti-epileptic drugs; epilepsy patients who cannot tolerate the adverse reactions of traditional anti-epileptic drugs; severe epilepsy patients with complex partial seizures or secondary systemic seizures, and children with Lennox-Gostaut syndrome. The chemical name of gabapentin is 1-(aminomethyl)cyclohexaneacetic acid, and its structural formula is as follows:
[0003]
[0004] Gabapentin has a similar structure to γ-aminobutyric acid (GABA), and its main mechanisms of action are currently believed to be the following: antagonizing N-methyl-D-aspartate (NMDA) receptors; producing GABA-like inhibitory effects, increasing GABA synthesis, and reducing GABA degradation; inhibiting calcium ion channels in the postsynaptic membrane, blocking abnormal discharges of diseased nerves; and exerting its effects by adjusting the processing of abnormal sensory information in the spinal cord through its effects on peripheral nerves or most of the central nervous system.
[0005] Impurity research is an important part of the drug development process, which is directly related to the quality control and drug safety of the drug. By controlling the impurities in the drug product, the quality and safety of the product can be guaranteed. The impurities in the drug mainly come from by-products in the synthesis process and the degradation of the drug.
[0006] 2-[(3-oxo-2-azaspiro[4.5]decan-2-yl)methyl]-2-azaspiro[4.5]decan-3-one is a gabapentin bisamide impurity and a major impurity produced in the gabapentin production process. It was retrieved from the Reaxys database and included in PubChem (National Center for Biotechnology Information's organic small molecule biological activity database) on October 14, 2021, with CID number 169444120, and its name is Methylene bis(Gabapentinlactam). The content of gabapentin bisamide impurity is related to the quality of gabapentin finished products.
[0007] At present, 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one is generally separated from gabapentin raw materials by separation methods. However, since the content of this substance in gabapentin raw materials is extremely low, usually below 0.5%, it is difficult to obtain 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one in large quantities by separation and preparation methods. The commercially available 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one is usually expensive. However, there is no report on the synthesis method at present. There is no CAS number found in the SciFinder database search, and there is no literature report on the synthesis of this impurity. Summary of the invention
[0008] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one, which is used to solve the problem that 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one cannot be produced in large quantities in the prior art.
[0009] To achieve the above objectives and other related objectives, the present invention is achieved through the following technical solutions.
[0010] The present invention provides a method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one, comprising the following steps: mixing 2-azaspiro[4.5]decane-3-one shown in formula 2, formaldehyde or paraformaldehyde, and a solvent, adding an acidic catalyst, reacting, removing the solvent, and purifying to obtain 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one shown in formula 1, and the reaction structure is as follows:
[0011]
[0012] As described above, the method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of the present invention has the following beneficial effects:
[0013] The invention designs a preparation method route of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one, and synthesizes the target impurity in a targeted manner. After testing, the synthesized target impurity has a purity of more than 97%, which meets the requirements of reference materials for drug research and declaration, and the cost is much lower than the market price. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 It is shown that the 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of the present invention 1 H-NMR spectrum.
[0015] Figure 2 It is shown that the 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of the present invention 13 C-NMR spectrum.
[0016] Figure 3 The LC-MS spectrum of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of the present invention is shown.
[0017] Figure 4 The HPLC spectrum of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of the present invention is shown. DETAILED DESCRIPTION
[0018] In order to make the purpose of the invention, technical solutions and beneficial technical effects of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0019] The extended part of this application and the effect description of the extended part, including but not limited to subsequent data analysis, mechanism description, etc.
[0020] The present invention provides a specific implementation method of a method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one.
[0021] The control of drug impurities is the key to drug quality control, because impurities in drugs may reduce the efficacy of drugs and even cause harm to human health. Therefore, scientific and rigorous analysis and research should be conducted on impurities generated during the production and storage of raw materials.
[0022] In the study of impurities, the use of impurity reference substances for detection is a scientific and effective method. In addition to the characteristics of general reference substances, impurity reference substances also have their own characteristics: difficult preparation, small sample quantity and high price. For example, the price of the impurity reference substance of the present invention is 100mg / 14000RMB. The sources of impurity reference substances include: preparation of liquid phase enrichment and directional synthesis. The World Health Organization stipulates that the purity of impurity reference substances should not be less than 95%.
[0023] The present invention provides a method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one, comprising the following steps: mixing 2-azaspiro[4.5]decane-3-one shown in formula 2, formaldehyde or paraformaldehyde, and a solvent, adding an acidic catalyst, reacting, removing the solvent, and purifying to obtain 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one shown in formula 1, and the reaction structure is as follows:
[0024]
[0025] In some embodiments of the present invention, the mass ratio of 2-azaspiro[4.5]decane-3-one represented by Formula 2, formaldehyde or polyformaldehyde, and solvent is (4-11):(0.1-0.8):(4-21).
[0026] In some specific embodiments of the present invention, the mass ratio of 2-azaspiro[4.5]decane-3-one represented by Formula 2, formaldehyde or polyformaldehyde, and solvent can be (4-8):(0.1-0.4):(4-15), (8-11):(0.4-0.8):(15-21); typical but non-limiting examples are 4:0.1:4, 8:0.4:15, and 11:0.8:21.
[0027] In some embodiments of the present invention, the degree of polymerization of the paraformaldehyde is 8-100.
[0028] In some embodiments of the present invention, the equivalent of the acidic catalyst is 0.2-0.5 eq of 2-azaspiro[4.5]decane-3-one shown in Formula 2.
[0029] In some specific embodiments of the present invention, the equivalent of the acidic catalyst can be 0.2-0.4eq, 0.4-0.5eq of 2-azaspiro[4.5]decane-3-one shown in Formula 2, typically but not limiting, for example, 0.2eq, 0.4eq, 0.5eq.
[0030] In some embodiments of the present invention, the reaction temperature is 50-110°C.
[0031] In some specific embodiments of the present invention, the reaction temperature can be 50-55°C, 55-60°C, 60-75°C, 75-80°C, 80-110°C; typical but non-limiting examples are 50°C, 55°C, 60°C, 75°C, 80°C, 110°C.
[0032] In some embodiments of the present invention, the reaction time is 4-8 hours.
[0033] In some specific embodiments of the present invention, the reaction time may be 4-6 h, 6-8 h; typically but not limiting, for example, it may be 4 h, 6 h, 8 h.
[0034] In some embodiments of the present invention, the solvent is selected from any one of 1,4-dioxane, toluene and tetrahydrofuran; preferably, the solvent is 1,4-dioxane.
[0035] In some embodiments of the present invention, the purification is performed by column chromatography; preferably, the eluent of the column chromatography is selected from one or more of ethyl acetate and n-heptane; further preferably, the eluent consists of ethyl acetate and n-heptane in a mass ratio of (1-3): (1-8); further preferably, the eluent consists of ethyl acetate and n-heptane in a mass ratio of 1:6.
[0036] In some embodiments of the present invention, the acidic catalyst is selected from any one of hydrochloric acid, sulfuric acid, phosphoric acid, benzenesulfonic acid, aluminum chloride, and oxalyl chloride.
[0037] In some embodiments of the present invention, the solvent is removed by vacuum distillation; preferably, the temperature of the vacuum distillation is 90-98°C, specifically, 90-95°C, 95-98°C, typically but not limitatively, for example, 90°C, 95°C, 98°C.
[0038] In some embodiments of the present invention, the purity of the 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one is greater than 97%.
[0039] The present invention is further described below by way of examples, but the scope of the present invention is not limited thereto.
[0040] When the embodiment gives a numerical range, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. If specific conditions are not specified in the embodiment, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are conventional products that can be purchased commercially. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any method, equipment, and material of the prior art similar or equivalent to the method, equipment, and material in the embodiments of the present invention can also be used to realize the present invention.
[0041] The yield calculation method in the following examples is actual yield / theoretical yield × 100%, and the purity is determined by high performance liquid chromatography. NMR spectra were obtained on a BRUKER400. Unless otherwise specified, the solvents CDCl3, CD3OD and DMSO-d 6 All were purchased from Shanghai Titan Technology Co., Ltd.
[0042] Example
[0043] Example 1
[0044] The preparation method of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of this embodiment comprises the following steps: adding 10.00 g of the compound 2-azaspiro[4.5]decane-3-one shown in formula 2 to 10.40 g of 1,4-dioxane. At room temperature, 2.94 g of 50% sulfuric acid aqueous solution was added dropwise. After 30 minutes of addition, the mixture was stirred at room temperature for 30 minutes, and 0.68 g of 40% formaldehyde aqueous solution was added. The mixture was heated to 60°C and reacted for 6 hours. After the reaction, 1,4-dioxane was removed by reduced pressure distillation at 95°C to obtain a product, and the product was purified by column chromatography to obtain 13.54g of white powder, which was 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one shown in Formula 1, with a yield of 65.67% and a purity of 98.07%. During column chromatography, the eluent was composed of ethyl acetate and n-heptane in a mass ratio of 1:6.
[0045] Example 2
[0046] The preparation method of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one of this embodiment comprises the following steps: adding 10.00 g of the compound 2-azaspiro[4.5]decane-3-one shown in formula 2 to 20 ml of toluene. At room temperature, 1.82 g of 30% concentrated hydrochloric acid is added dropwise. After 30 minutes of dropwise addition, the mixture is stirred at room temperature for 30 minutes, and 0.30 g of paraformaldehyde is added. The mixture is heated to 80°C and reacted for 6 hours. After the reaction, toluene was removed by reduced pressure distillation at 95°C to obtain a product, and the product was purified by column chromatography to obtain 14.75 g of a white powder, which was 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one shown in Formula 1, with a yield of 71.43% and a purity of 97.69%. During column chromatography, the eluent was composed of ethyl acetate and n-heptane in a mass ratio of 1:6.
[0047] Example 3
[0048] A method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one in this embodiment comprises the following steps: dissolving 5.00 g of the compound 2-azaspiro[4.5]decane-3-one shown in Formula 2 and 0.2 g of paraformaldehyde in 5.0 g of toluene. At room temperature, 1.0 g of p-toluenesulfonic acid is added to the reaction. The temperature is raised to 75° C. and the reaction is performed for 6 hours. After the reaction is completed, toluene is removed by reduced pressure distillation at 95° C. to obtain a brown oil. The brown oil is purified by column chromatography to obtain 7.06 g of white powder, which is 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one shown in Formula 1, with a yield of 68.36% and a purity of 98.11%. Wherein, during column chromatography, the eluent is composed of ethyl acetate and n-heptane in a mass ratio of 1:6.
[0049] Performance Testing
[0050] 1. Nuclear Magnetic Resonance
[0051] Detection instrument: Swiss Bruker AVANCE AV 400 superconducting pulse Fourier transform nuclear magnetic resonance spectrometer;
[0052] The 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one prepared in Example 1 was tested by hydrogen and carbon spectra using 400 MHz nuclear magnetic resonance, the solvent was deuterated chloroform, and the spectrum was as follows: Figure 1 and Figure 2 shown.
[0053] 2. Liquid chromatography, mass spectrometry
[0054] Detection instrument: Agilent LC-MS / MS chromatograph Qtof 1290-6546;
[0055] Detection method: Refer to "Chinese Pharmacopoeia 2020 Edition Part IV General Chapter 0431 Mass Spectrometry".
[0056] The molecular weight of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one prepared in Example 1 was measured, and the chromatogram was as follows: Figure 3 shown.
[0057] 3. High performance liquid chromatography
[0058] Detection instrument: Waters e2695 high performance liquid chromatograph; chromatographic column: octadecylsilane bonded silica gel as filler (chromatographic column: Waters Atlantis T3 4.6x250mm, 5um); mobile phase A: mixed solution (phosphate buffer 94%, acetonitrile 6%), phosphate buffer (94:6); mobile phase B: acetonitrile flow rate: 1.5ml / min; column temperature: 40°C; detection wavelength: 210nm, mobile phase gradient is shown in Table 1. Among them, the preparation method of phosphate buffer is: take 1.2g of potassium dihydrogen phosphate, add 940ml of water to dissolve, and adjust the pH value to 6.6 with 5mol potassium hydroxide solution.
[0059] Table 1 Chromatographic mobile phase gradient elution program
[0060]
[0061] The purity of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one prepared in Example 1 was measured, and the chromatogram was as follows: Figure 4 shown.
[0062] Results Analysis
[0063] 1. Nuclear Magnetic Resonance Analysis
[0064] 1.1 Hydrogen spectrum
[0065]
[0066] Table 2
[0067]
[0068] Combination Figure 1 As can be seen from Table 2,
[0069] 1, 2, 3, 4, 5 and 1', 2', 3', 4', 5' δ (1.44), multiple peaks with 20 protons, representing the methylene proton peak -CH2 of the cyclohexyl group in the spiro ring structure, and it is a symmetrical structure;
[0070] 6,6'δ(3.12), single peak with 4 protons, representing the proton peak -CH2 on the methylene group of the cyclic amine in the spirocyclic structure, and it is a symmetrical structure;
[0071] 7,7'δ(2.24), single peak with 4 protons, representing the proton peak -CH2 on the methylene group of cyclopentylamine in the spiro ring structure, and it is a symmetrical structure;
[0072] 8δ (4.74), a single peak with 2 protons, represents the proton peak -CH2 on the methylene connecting the two spiro rings.
[0073] Theoretically, this product contains 30 hydrogen atoms. Figure 1 of 1 Analysis of the H NMR spectrum shows that the compound has 30 hydrogen atoms, and the chemical shift assignments are completely consistent with the molecular structure.
[0074] 1.2 Carbon spectrum
[0075]
[0076]
[0077]
[0078] Combining Table 3 and Figure 2 It can be seen that
[0079] 13 C NMR analysis (δ36.81) is the methylene proton peak -CH2 with carbon numbers 1, 1', 5, 5' on the cyclohexyl group in the spiro ring structure;
[0080] 13 C NMR analysis (δ22.70) is the methylene proton peak -CH2 with carbon numbers 2, 2', 4, 4' on the cyclohexyl group in the spiro ring structure;
[0081] 13 C NMR analysis (δ25.48) is the methylene proton peak -CH2 with carbon numbers 3,3' on the cyclohexyl group in the spiro ring structure;
[0082] 13 C NMR analysis (δ36.36) is the methylene proton peak -CH2 with carbon numbers 6, 6' on the cyclohexyl group in the spiro ring structure;
[0083] 13 C NMR analysis (δ48.75) is the methylene proton peak -CH2 with carbon number 7,7' on the cyclopentylamine in the spiro ring structure;
[0084] 13 C NMR analysis (δ43.92) is the methylene proton peak -CH2 with carbon number 8, 8' on the cyclopentylamine in the spiro ring structure;
[0085] 13 C NMR analysis (δ175.05) is the acyl proton peak -C=O- with carbon numbers 9, 9' on the cyclopentylamine in the spiro ring structure;
[0086] 13 C NMR analysis (δ57.46) showed that it was a methylene group -CH2 with carbon number 10 connecting two spiro rings.
[0087] from13 Analysis of the C NMR spectrum shows that the compound has a total of 19 carbon atoms, and the number and position of high-field and low-field carbon atoms are completely consistent with the molecular structure.
[0088] 2. Liquid chromatography and mass spectrometry analysis
[0089] Combination Figure 3 It can be seen that according to the analysis of the LC-MS spectrum, the following structural information can be obtained, see Table 4.
[0090] Table 4
[0091] m / z Fragment ions Remark 319.2415 <h2 style=";text-align:left;direction:ltr"><![CDATA[C <h2 style=";text-align:left;direction:ltr"> 19 <h2 style=";text-align:left;direction:ltr"> H<h2 style=";text-align:left;direction:ltr"> 30 <h2 style=";text-align:left;direction:ltr"> N2O2<h2 style=";text-align:left;direction:ltr"> +. <h2 style=";text-align:left;direction:ltr"> ]]><h2 style=";text-align:left;direction:ltr"> Molecular ion peak
[0092] 3. High performance liquid chromatography analysis
[0093] Combination Figure 4 It can be seen that after high performance liquid chromatography detection, the initial purity of 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one prepared by the preparation method of the present invention is 98.07%.
[0094] Combination 1 H NMR, 13 C NMR and LC-MS confirmed that the molecular composition of the compound was C 19 H 30 The structure of N2O2 is shown below.
[0095]
[0096] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one, characterized in that: The method comprises the following steps: mixing 2-azaspiro[4.5]decane-3-one shown in formula 2, formaldehyde or polyformaldehyde, and a solvent, adding an acidic catalyst, reacting, removing the solvent, and purifying to obtain 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one shown in formula 1, and the reaction structure is as follows:
2. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: The mass ratio of 2-azaspiro[4.5]decane-3-one represented by formula 2, formaldehyde or polyformaldehyde, and solvent is (4-11):(0.1-0.8):(4-21).
3. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: The equivalent of the acidic catalyst is 0.2-0.5 eq of 2-azaspiro[4.5]decane-3-one shown in Formula 2.
4. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: The reaction temperature is 50-110°C; preferably, the reaction temperature is 60-80°C.
5. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: The reaction time is 4-8 hours; preferably, the reaction time is 6-7 hours.
6. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: The polymerization degree of the paraformaldehyde is 8-100.
7. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: Also includes any one or more of the following features: 11) The solvent is selected from any one of 1,4-dioxane, toluene and tetrahydrofuran; 12) The purification is performed by column chromatography; 13) The acidic catalyst is selected from any one of hydrochloric acid, sulfuric acid, phosphoric acid, benzenesulfonic acid, and aluminum chloride; 14) The solvent is removed by distillation under reduced pressure.
8. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 7, characterized in that: Also includes any one or more of the following features: 111) The solvent is 1,4-dioxane; 121) The eluent for column chromatography is selected from one or more of ethyl acetate and n-heptane; 131) The acidic catalyst is selected from any one of hydrochloric acid, sulfuric acid, phosphoric acid, benzenesulfonic acid and aluminum chloride; 141) The temperature of the reduced pressure distillation is 90-98°C.
9. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 8, characterized in that: The eluent is composed of ethyl acetate and n-heptane in a mass ratio of (1-3): (1-8).
10. The method for preparing 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one according to claim 1, characterized in that: The purity of the 2-[(3-oxo-2-azaspiro[4,5]decane-2-yl)methyl]-2-azaspiro[4,5]decane-3-one is >97%.
Citation Information
Patent Citations
Separation and preparation method of trace impurities D in gabapentin bulk drug
CN112679412A
Gabapentin impurity and preparation method thereof
CN113698339A
Chemical synthesis method of gabapentin impurity D
CN118108656A
Method for determining impurity a in dosage forms of gabapentin
RU2773851C1
